Carsten Gram Hansen

Dr. Carsten Gram Hansen

University of Edinburgh Centre for Inflammation Research, Queen's Medical Research Institute, Edinburgh bioQuarter, United Kingdom

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2015 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
TMToshiro Moroishi
Toshiro Moroishi
Carsten Gram HansenCarsten Gram Hansen
Carsten Gram Hansen
KGKun-Liang Guan
Kun-Liang Guan

1 September 2015 in Trends in Cell Biology
Verified
Journal Article
Closed access
Carsten Gram HansenCarsten Gram Hansen
Carsten Gram Hansen
TMToshiro Moroishi
Toshiro Moroishi
KGKun-Liang Guan
Kun-Liang Guan

9 March 2015 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
JMJung-Soon Mo
Jung-Soon Mo
ZMZhipeng Meng
Zhipeng Meng
YKYoung Chul Kim
Young Chul Kim
HPHyun Woo Park
Hyun Woo Park
Carsten Gram HansenCarsten Gram Hansen
Carsten Gram Hansen
KGKun-Liang Guan
Kun-Liang Guan
YAP (Yes-associated protein) is a transcription co-activator in the Hippo tumour suppressor pathway and controls cell growth, tissue homeostasis and organ size. YAP is inhibited by the kinase Lats, which phosphorylates YAP to induce its cytoplasmic localization and proteasomal degradation. YAP induces gene expression by binding to the TEAD family transcription factors. Dysregulation of the Hippo–YAP pathway is frequently observed in human cancers. Here we show that cellular energy stress induces YAP phosphorylation, in part due to AMPK-dependent Lats activation, thereby inhibiting YAP activity. Moreover, AMPK directly phosphorylates YAP Ser 94, a residue essential for the interaction with TEAD, thus disrupting the YAP–TEAD interaction. AMPK-induced YAP inhibition can suppress oncogenic transformation of Lats-null cells with high YAP activity. Our study establishes a molecular mechanism and functional significance of AMPK in linking cellular energy status to the Hippo–YAP pathway.

5 October 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZMZhipeng Meng
Zhipeng Meng
TMToshiro Moroishi
Toshiro Moroishi
VMViolaine Mottier-Pavie
Violaine Mottier-Pavie
SPSteven W. Plouffe
Steven W. Plouffe
Carsten Gram HansenCarsten Gram Hansen
Carsten Gram Hansen
KGKun-Liang Guan
Kun-Liang Guan
The Hippo pathway plays a central role in tissue homoeostasis, and its dysregulation contributes to tumorigenesis. Core components of the Hippo pathway include a kinase cascade of MST1/2 and LATS1/2 and the transcription co-activators YAP/TAZ. In response to stimulation, LATS1/2 phosphorylate and inhibit YAP/TAZ, the main effectors of the Hippo pathway. Accumulating evidence suggests that MST1/2 are not required for the regulation of YAP/TAZ. Here we show that deletion of LATS1/2 but not MST1/2 abolishes YAP/TAZ phosphorylation. We have identified MAP4K family members—Drosophila Happyhour homologues MAP4K1/2/3 and Misshapen homologues MAP4K4/6/7—as direct LATS1/2-activating kinases. Combined deletion of MAP4Ks and MST1/2, but neither alone, suppresses phosphorylation of LATS1/2 and YAP/TAZ in response to a wide range of signals. Our results demonstrate that MAP4Ks act in parallel to and are partially redundant with MST1/2 in the regulation of LATS1/2 and YAP/TAZ, and establish MAP4Ks as components of the expanded Hippo pathway.

1 April 2010 in Trends in Cell Biology
Verified
Journal Article
Closed access
Carsten Gram HansenCarsten Gram Hansen
Carsten Gram Hansen
BNBen J. Nichols
Ben J. Nichols

4 February 2022 in Clinical Science
Verified
Journal Article
Open access
PDF file
RCRichard Cunningham
Richard Cunningham
Carsten Gram HansenCarsten Gram Hansen
Carsten Gram Hansen
Tumorigenesis is a highly complex process, involving many interrelated and cross-acting signalling pathways. One such pathway that has garnered much attention in the field of cancer research over the last decade is the Hippo signalling pathway. Consisting of two antagonistic modules, the pathway plays an integral role in both tumour suppressive and oncogenic processes, generally via regulation of a diverse set of genes involved in a range of biological functions. This review discusses the history of the pathway within the context of cancer and explores some of the most recent discoveries as to how this critical transducer of cellular signalling can influence cancer progression. A special focus is on the various recent efforts to therapeutically target the key effectors of the pathway in both preclinical and clinical settings.